New Challenge to IP Innovation

31 August 2016 Pharmaceutical Executive Publication
Authors: Stephen B. Maebius

Pharmaceutical Executive

Partner Steve Maebius contributed an article to Pharmaceutical Executive, “New Challenge to IP Innovation,” on August 31, 2016. The article provided an overview of the use of Inter Partes Reviews (IPRs) in the pharmaceutical industry, for both generic and originator companies. Maebius discussed the findings of a survey that analyzed 111 IPR filings by generic drug companies against pharmaceutical patents and highlighted key considerations for originator companies.

Related Services